{"filings":[{"id":554996,"accession_number":"0001555280-26-000026","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2026-05-20T20:23:35+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares Q3 2026 dividend of $0.53 per share","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend set at $0.53 per share for Q3 2026.","Payable on September 1, 2026; record date July 20, 2026.","Dividend marks continued quarterly payout to common stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93606,"accession_number":"0001555280-26-000021","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q1 revenue flat organic; cuts FY 2026 guidance on softer demand and competition","event_type":"earnings","confidence":"high","bullets":["Revenue $2.3B, +3% reported but flat organic; net income $601M ($1.42 EPS), flat YoY.","Adjusted net income $646M ($1.53 EPS), +2% reported, +1% organic; guidance cut: FY rev $9.68-9.96B (2-5% organic growth).","U.S. segment revenue down 8% on competitive pressure and macro price sensitivity; International up 10% organic.","Acquisition of Neogen animal genomics business announced March 2, expected to close H2 2026.","Pipeline includes >12 potential blockbusters; recent approvals in Canada, Thailand, Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":2262000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105376,"accession_number":"0001555280-26-000008","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q4 2025 revenue $2.4B (+3%), EPS $1.37; FY26 guidance $9.825-10.025B","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $2.4B (+3% reported, +4% organic); net income $603M (EPS $1.37, +6%).","Full year 2025 revenue $9.5B (+2% reported, +6% organic); adjusted EPS $6.41 (+8% reported).","FY 2026 guidance: revenue $9.825-10.025B (organic growth 3-5%); adjusted EPS $7.00-7.10.","U.S. segment revenue flat organically; International up 7% organic driven by parasiticide and livestock growth.","Acquired VPG in UK/Ireland; received approvals for long-acting OA pain mAbs Lenivia (dog) and Portela (cat) in Canada/EU."],"consensus_eps_estimate":null,"consensus_eps_actual":6.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":9467000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105375,"accession_number":"0001555280-26-000003","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares Q2 2026 dividend of $0.53 per share","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.53 per share declared for second quarter of 2026.","Payable on June 2, 2026 to holders of record as of April 20, 2026.","Quarterly dividend rate unchanged from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121665,"accession_number":"0001193125-25-324853","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Zoetis issues $2B of 0.25% convertible notes due 2029; proceeds for stock buyback and capped calls","event_type":"debt","confidence":"high","bullets":["Aggregate principal $2.0B (including $250M option exercised); 0.25% semi-annual interest; matures June 15, 2029.","Initial conversion price ~$148.20/share, representing a 22.5% premium to December 15, 2025 closing price.","Capped calls with six counterparties cover ~13.5M shares; cap price $211.715/share to offset dilution.","Net proceeds ~$1.9696B: $186.6M for capped calls, $248M for concurrent share repurchases, remainder ~$1.535B for additional buybacks by Q1 2026.","Existing $6B share repurchase program used; technical provision in revolving credit facility waived to permit early conversions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121664,"accession_number":"0001555280-25-000282","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.53 per share quarterly dividend for Q1 2026","event_type":"dividend","confidence":"high","bullets":["Zoetis declared a quarterly dividend of $0.53 per share for Q1 2026.","Record date is January 20, 2026; payment date is March 3, 2026.","Dividend amount remains unchanged from the prior quarterly rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121663,"accession_number":"0001555280-25-000280","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zoetis posts Innovation Webcast presentation; no material financial details provided","event_type":"other_material","confidence":"low","bullets":["Innovation Webcast scheduled for Dec 2, 2025 at 8:30 a.m. ET.","Presentation filed as Exhibit 99.1 but content not fully available in filing text.","No specific financial guidance, product updates, or operational metrics released.","Investors directed to presentation for potential pipeline or strategy details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121662,"accession_number":"0001555280-25-000272","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q3 adjusted EPS $1.70 (+8%); revenue $2.4B (+4% organic); FY guidance narrowed","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $2.4B (+1% reported; +4% organic operational); net income $721M, $1.63 diluted EPS (+9% YoY).","Adjusted net income $754M, $1.70 adjusted diluted EPS (+8% reported; +12% organic operational).","U.S. segment revenue $1.3B (-2% reported, +3% organic); International $1.1B (+3% reported, +6% organic).","Updated FY2025 revenue guidance $9.400-9.475B (5.5-6.5% organic growth); adjusted EPS $6.30-6.40 maintained.","Regulatory milestones: Lenivia approved in Canada/EU for canine OA pain; Portela approved in EU for feline OA."],"consensus_eps_estimate":null,"consensus_eps_actual":4.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":7080000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121661,"accession_number":"0001555280-25-000266","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zoetis appoints Stephanie Tilenius to Board, effective Dec 1, 2025","event_type":"leadership","confidence":"high","bullets":["Stephanie Tilenius appointed to Zoetis Board, effective December 1, 2025.","Board size increases from 12 to 13 members upon her appointment.","No arrangements with third parties or related party transactions reported.","Ms. Tilenius will participate in standard non-employee director compensation program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121660,"accession_number":"0001555280-25-000264","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.50 per share Q4 dividend, payable Dec 2, 2025","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.50 per share declared for Q4 2025.","Payable on December 2, 2025, to holders of record as of October 31, 2025.","Quarterly dividend rate unchanged from prior quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138337,"accession_number":"0001193125-25-189772","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Zoetis enters $1.25B revolver, replaces 2022 facility; can increase to $1.75B","event_type":"debt","confidence":"high","bullets":["New five-year $1.25B senior unsecured revolving credit facility, maturing August 2030.","Facility replaces existing $1.25B credit agreement scheduled to expire December 2027.","JPMorgan Chase Bank, N.A. acts as administrative agent; Barclays, Bank of America, Citibank, MUFG as syndication agents.","Loans bear interest at base rate or term SOFR plus applicable margin based on credit ratings.","Financial covenant requires not exceeding a maximum total leverage ratio; customary affirmative/negative covenants apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138336,"accession_number":"0001193125-25-182451","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zoetis issues $1.85B in senior notes: $850M at 4.150% due 2028, $1B at 5.000% due 2035","event_type":"debt","confidence":"high","bullets":["Issued $850M 4.150% Senior Notes due 2028 and $1B 5.000% Senior Notes due 2035.","Notes issued under existing indenture with Deutsche Bank Trust Company Americas as trustee.","Underwriters include Barclays, BofA, Citigroup, J.P. Morgan, and MUFG Securities.","Offering registered on Form S-3; no specific use of proceeds disclosed in the 8-K.","Debt issuance increases total long-term debt by $1.85B; interest expense will rise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138335,"accession_number":"0001555280-25-000259","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zoetis Q2 revenue $2.5B (+4% reported, +8% organic); raises FY2025 guidance","event_type":"earnings","confidence":"high","bullets":["Reported net income $718M ($1.61 diluted EPS), up 15% YoY; adjusted EPS $1.76, up 13%.","U.S. segment revenue $1.4B (+4% reported, +7% organic); companion animal product sales up 9%.","International segment revenue $1.1B (+3% reported, +9% organic); livestock sales up 10% organic.","Raised FY2025 revenue guidance to $9.45-9.60B (organic growth 6.5-8.0%); adjusted EPS $6.30-6.40.","Simparica Trio gained new label in Japan; avian influenza vaccine conditionally licensed for U.S. dairy cattle."],"consensus_eps_estimate":null,"consensus_eps_actual":3.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":4680000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155783,"accession_number":"0001555280-25-000213","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Zoetis appoints Mark Stetter to board; Robert Scully retires","event_type":"leadership","confidence":"high","bullets":["Robert Scully retired from Zoetis board effective May 21, 2025, under director retirement policy.","Mark Stetter elected to board at annual meeting; received 371.2M votes for, 0.4M against.","Shareholders approved executive compensation (334.2M for, 35.2M against) and ratified KPMG as auditor (384.8M for, 7.6M against).","Shareholder proposal to improve special meeting process failed with 50.4M for vs. 320.7M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155782,"accession_number":"0001555280-25-000209","cik":1555280,"company_name":"Zoetis Inc.","ticker":"ZTS","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zoetis declares $0.50/share quarterly dividend for Q3 2025","event_type":"dividend","confidence":"high","bullets":["Dividend of $0.500 per share declared for third quarter 2025.","Payable on September 3, 2025 to stockholders of record as of July 18, 2025.","Routine quarterly dividend declaration with no change in amount indicated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}